172 related articles for article (PubMed ID: 37410241)
1. Evaluation of FGFR Alteration Status in Urothelial Tumors.
Bahlinger V; Eckstein M; Hartmann A; Stöhr R
Methods Mol Biol; 2023; 2684():283-291. PubMed ID: 37410241
[TBL] [Abstract][Full Text] [Related]
2. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
[TBL] [Abstract][Full Text] [Related]
6. FGFR alterations in urothelial carcinoma: Picking the right target.
Hubert P; Selmani Z; Loriot Y; Thiery-Vuillemin A
Bull Cancer; 2021 Jun; 108(6):566-570. PubMed ID: 34020787
[No Abstract] [Full Text] [Related]
7. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
9. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
10. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
Franza A; Pirovano M; Giannatempo P; Cosmai L
Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
[TBL] [Abstract][Full Text] [Related]
11. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Benjamin DJ; Hsu R
Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
[TBL] [Abstract][Full Text] [Related]
12. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
15. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
[TBL] [Abstract][Full Text] [Related]
16. Erdafitinib to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
18. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
19. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Pezzicoli G; Ciciriello F; Musci V; Minei S; Biasi A; Ragno A; Cafforio P; Rizzo M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674231
[TBL] [Abstract][Full Text] [Related]
20. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]